Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma

This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30). All subjects must have histologically confirmed World Health Organization (WHO) Grade IV glioblastoma. Participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma is made. Other WHO grade IV glial neoplasms such as gliosarcoma are NOT eligible. Subjects for this study will be recruited from the patient population that present to the Department of Neurosurgery at the Hospital of the University of Pennsylvania for evaluation and treatment of their brain tumors.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  glioblastoma
• Age: Between 18 Years - 99 Years
• Gender: All